| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10016573 | HBV | ENSG00000102468.11 | protein_coding | HTR2A | No | No | 3356 | P28223 |
| TVIS44041305 | HTLV-1 | ENSG00000102468.11 | protein_coding | HTR2A | No | No | 3356 | P28223 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR2A |
|---|---|
| DrugBank ID | DB01392 |
| Drug Name | Yohimbine |
| Target ID | BE0000451 |
| UniProt ID | P28223 |
| Regulation Type | antagonist |
| PubMed IDs | 8032658; 6136920; 20036429 |
| Citations | Baxter GS, Murphy OE, Blackburn TP: Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol. 1994 May;112(1):323-31.@@Kaumann AJ: Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1983 Jun;323(2):149-54.@@Holmes A, Quirk GJ: Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine. Trends Pharmacol Sci. 2010 Jan;31(1):2-7. doi: 10.1016/j.tips.2009.10.003. Epub 2009 Dec 28. |
| Groups | Approved; Investigational; Vet_approved |
| Direct Classification | Yohimbine alkaloids |
| SMILES | [H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2 |
| Pathways | |
| PharmGKB | PA451946 |
| ChEMBL | CHEMBL15245 |
